<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium channel blockers in heart failure with reduced ejection fraction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium channel blockers in heart failure with reduced ejection fraction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Calcium channel blockers in heart failure with reduced ejection fraction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Calcium channel blockers should generally be avoided in patients with heart failure with reduced ejection fraction (HFrEF) since they provide no functional or mortality benefit and some first generation agents may worsen outcomes [<a href="#rid1">1</a>].</p><p>The clinical trials that have evaluated the use of calcium channel blockers in patients with HFrEF will be reviewed here. The use of calcium channel blockers in the treatment of HF with preserved ejection fraction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Secondary therapies'</a>.)</p><p class="headingAnchor" id="H4250051374"><span class="h1">FIRST GENERATION AGENTS</span><span class="headingEndMark"> — </span>Calcium channel blockers might be expected to have beneficial effects in systolic HF by reducing peripheral vasoconstriction and thereby reducing left ventricular afterload. However, these agents also have variable degrees of negative inotropic activity, and several studies demonstrated greater clinical deterioration in patients treated with <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> and <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> compared with placebo or <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> [<a href="#rid2">2,3</a>]. As a result, these drugs have generally been avoided in patients with systolic HF, even for the treatment of coexisting angina or hypertension.</p><p class="headingAnchor" id="H2"><span class="h2">Nifedipine</span><span class="headingEndMark"> — </span>The effect of <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> in HFrEF depends, in part, upon the baseline hemodynamic status of the patient. Short-term use of the drug can cause hemodynamic deterioration when there is evidence of more severe HF, as manifested by high plasma renin activity, hyponatremia, and elevated right atrial pressure [<a href="#rid4">4</a>].</p><p>The adverse effects of long-term therapy with <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> were illustrated in a randomized, double-blind, crossover study of 28 patients with New York Heart Association (NYHA) class II or III HFrEF (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 1</a>); nifedipine, with and without <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>, was compared with isosorbide dinitrate alone [<a href="#rid2">2</a>]. Eight weeks of therapy with nifedipine alone or in combination with isosorbide dinitrate resulted in a significantly higher incidence of hospitalization (24 and 26 versus 0 percent with isosorbide dinitrate alone), episodes of worsening HF (9 and 21 versus 5), and premature discontinuation of therapy due to clinical deterioration or other side effects (29 and 19 versus 5 percent).</p><p class="headingAnchor" id="H3"><span class="h2">Verapamil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">Verapamil</a> does not appear to be effective in patients with HF after an acute myocardial infarction (MI), although it does not increase mortality. This was illustrated by the DAVIT II trial, which randomly assigned 1775 patients with a recent MI to verapamil (360 mg/day) or placebo; therapy was continued for a mean of 16 months [<a href="#rid5">5</a>]. In patients with HF during hospitalization, verapamil had no effect on mortality (18 percent in both groups) or the combined end point of death or reinfarction (25 percent in both groups). (See  <a class="medical medical_review" href="/z/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction", section on 'Calcium channel blockers'</a> and  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Calcium channel blockers'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Diltiazem</span><span class="headingEndMark"> — </span>The role of <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> in patients with HF has been evaluated in two randomized trials. The results are conflicting.</p><p class="headingAnchor" id="H5"><span class="h2">Multicenter Diltiazem Postinfarction trial</span><span class="headingEndMark"> — </span>The Multicenter <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">Diltiazem</a> Postinfarction Trial (MDPIT) randomly assigned 2466 patients with an MI to therapy with diltiazem or placebo [<a href="#rid6">6</a>]. After a mean follow-up of 25 months, patients with pulmonary congestion on chest x-ray who were treated with diltiazem had a significant increase in cardiac mortality or recurrent nonfatal infarction compared with placebo (hazard ratio 1.41). In contrast, diltiazem reduced the incidence of cardiac mortality and risk of recurrent nonfatal infarction in patients without pulmonary congestion (hazard ratio 0.77).</p><p>A subsequent analysis found a similar effect of <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> when analyzed by left ventricular ejection fraction (LVEF) [<a href="#rid3">3</a>]. Among 623 patients with an LVEF ≤0.40, the incidence of late HF episodes was higher in those taking diltiazem (21 versus 12 percent for placebo). The incidence of late HF increased progressively with decrements in baseline LVEF. In comparison, diltiazem had no adverse effect in patients with an LVEF above 40 percent.</p><p>An increase in recurrent infarction in diltiazem-treated patients with left ventricular dysfunction was also suggested in a retrospective analysis of almost 7000 patients entered into the SOLVD trials, most of whom had a remote infarction and one-third of whom were taking a short-acting calcium channel blocker, primarily <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> [<a href="#rid7">7</a>]. However, such a deleterious effect of calcium channel blocker therapy was not seen in a retrospective analysis from the SAVE trial of 2231 patients who had asymptomatic left ventricular dysfunction after an acute infarction [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H6"><span class="h2">DiDi trial</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">Diltiazem</a> in Dilated Cardiomyopathy (DiDi) trial randomly assigned 186 patients with idiopathic dilated cardiomyopathy and New York Heart Association (NYHA) class II or III HF to diltiazem (60 or 90 mg TID) or placebo, added to standard therapy; however, only 153 patients completed the study [<a href="#rid9">9</a>]. The following results were noted at 24 months:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients in the <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> group had an improved cardiac index at rest and with exercise, improved stroke volume index, and increased exercise capacity compared with those taking placebo. However, there was an equivalent improvement in mean LVEF in both groups (8 versus 6 percent for placebo).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subjects taking <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> had a subjective increase in well-being compared with the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in transplant listing-free survival (85 versus 80 percent for placebo).</p><p></p><p>It is likely that the hemodynamic benefits of <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> in this trial were secondary to a vasodilator effect. These effects, which have also been seen with other vasodilators such as <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a>, have not translated into improvements in survival [<a href="#rid10">10</a>].</p><p>The difference in results between the MDPIT and DiDi trials likely reflects the different populations studied (eg, post-MI versus dilated cardiomyopathy), but in neither case do the results suggest a meaningful beneficial effect, and in some patients there was an adverse effect on outcomes.</p><p class="headingAnchor" id="H4220532143"><span class="h1">SECOND GENERATION AGENTS</span><span class="headingEndMark"> — </span>The second-generation calcium channel blockers <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> and <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a> have little or no negative inotropic activity at the usual therapeutic doses, and may be better tolerated than the other calcium channel blockers in patients with HF. As described below, studies with these drugs found neither benefit nor harm when used in patients with class II or III HF [<a href="#rid10">10,11</a>]. Thus, they appear to be safe and can be used for the treatment of hypertension or angina in patients with systolic HF [<a href="#rid12">12</a>]. However, in such patients, angiotensin converting enzyme (ACE) inhibitors and beta blockers, both of which improve patient survival, should be given first in patients with hypertension and beta blockers should be given first in patients with angina or atrial fibrillation.</p><p class="headingAnchor" id="H7"><span class="h2">Amlodipine</span><span class="headingEndMark"> — </span>The effect of <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a>, a calcium channel blocker devoid of negative inotropic effects but with vascular smooth muscle relaxing activity, was best evaluated in two major trials: PRAISE and PRAISE 2 [<a href="#rid13">13,14</a>]. Although the PRAISE trial suggested a survival benefit with amlodipine in patients with a nonischemic cardiomyopathy [<a href="#rid13">13</a>], this was not confirmed in PRAISE 2 [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H8"><span class="h3">PRAISE trial</span><span class="headingEndMark"> — </span>The PRAISE trial randomly assigned 1153 patients with class III or IV HF (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 1</a>) and a left ventricular ejection fraction (LVEF) below 30 percent to <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> or placebo, which were added to baseline therapy consisting of diuretics, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, and an ACE inhibitor [<a href="#rid13">13</a>]. The primary end point of the study was death from any cause and hospitalization for major cardiovascular events.</p><p>At 14 months, there was an insignificant 9 percent reduction in the primary end point with <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> (39 versus 42 percent for placebo) and an insignificant 16 percent reduction in all-cause mortality (<a class="graphic graphic_figure graphicRef70884" href="/z/d/graphic/70884.html" rel="external">figure 1</a>). The amlodipine-treated group had a higher incidence of peripheral edema (27 versus 18 percent) and pulmonary edema (15 versus 10 percent), but they were less likely to develop uncontrolled hypertension or angina. There did not appear to be an overall excess risk of cardiovascular adverse events for patients treated with amlodipine.</p><p>Thus, the PRAISE trial established the safety profile of <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> for the treatment of patients with left ventricular dysfunction, especially in those with a history of angina or hypertension. In a secondary retrospective analysis, the effect of amlodipine appeared to be dependent in part upon the etiology of the HF with improvement being seen in patients with a nonischemic cardiomyopathy [<a href="#rid15">15</a>]. However, this benefit was <strong>not</strong> confirmed in PRAISE 2.</p><p class="headingAnchor" id="H9"><span class="h3">PRAISE 2 trial</span><span class="headingEndMark"> — </span>The observation in the first PRAISE trial that there was a survival advantage with <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> in patients with nonischemic cardiomyopathy led to the PRAISE 2 trial, which evaluated the role of amlodipine in 1650 patients with a nonischemic cardiomyopathy [<a href="#rid14">14</a>]. After a follow-up of up to four years, there was no difference in mortality with amlodipine (34 versus 32 percent for placebo). When the results from PRAISE 2 were combined with those for patients with a nonischemic cardiomyopathy in PRAISE, no difference in mortality was observed. In addition, short-term data from the Amlodipine Exercise Trial found no benefit in parameters such as exercise tolerance, quality of life, or NYHA class [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Felodipine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">Felodipine</a>, like <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a>, is highly selective for vascular smooth muscle and it does not have negative inotropic activity. An initial placebo-controlled trial found that 12 weeks of therapy with felodipine added to standard therapy did not improve exercise time or signs and symptoms of HF [<a href="#rid17">17</a>]. This was followed by the large V-HeFT III trial.</p><p class="headingAnchor" id="H11"><span class="h3">V-HeFT III trial</span><span class="headingEndMark"> — </span>The V-HeFT III trial randomly assigned 450 men with chronic HF who were receiving <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> and diuretics to extended release <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a> (5 mg BID) or placebo [<a href="#rid11">11</a>]. The effect of felodipine on exercise tolerance, symptoms, and clinical outcome was evaluated after 12 weeks and at an average of 18 months of therapy. The following results were observed:</p><p class="bulletIndent1"><span class="glyph">●</span>At three months, there was no improvement in exercise tolerance, quality of life, or the need for hospitalization compared with placebo, despite a significant reduction in blood pressure and serum atrial natriuretic peptide levels, and a small but significant increase in left ventricular ejection fraction (LVEF). However, the beneficial effect on LVEF and atrial natriuretic peptide did not persist during long-term follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">Felodipine</a> prevented a worsening of exercise tolerance and quality of life at 18 months. The difference between exercise duration and quality of life between felodipine and placebo reached significance at 27 months after randomization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mortality and hospitalization rates were the same in the two groups (<a class="graphic graphic_figure graphicRef78557" href="/z/d/graphic/78557.html" rel="external">figure 2</a>). The only apparent side effect associated with <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a> therapy was peripheral edema.</p><p></p><p class="headingAnchor" id="H4149599338"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents to avoid in HFrEF</strong> – Calcium channel blockers (except <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> and <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a>) should generally be avoided in patients with heart failure with reduced ejection fraction (HFrEF) since they provide no functional or mortality benefit and some first-generation agents may worsen outcomes. (See <a class="local">'First generation agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents acceptable for use in HFrEF</strong> – <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">Amlodipine</a> and <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a> appear to be safe and well tolerated in patients with HFrEF and can be used for the treatment of hypertension or angina. However, angiotensin converting enzyme inhibitors and beta blockers, both of which improve survival among patients with HFrEF, should be given first in patients with hypertension and beta blockers should be given first in patients with angina or atrial fibrillation. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Pharmacologic therapy'</a> and <a class="local">'Second generation agents'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.</a></li><li><a class="nounderline abstract_t">Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82:1954.</a></li><li><a class="nounderline abstract_t">Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83:52.</a></li><li><a class="nounderline abstract_t">Packer M, Lee WH, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987; 10:1303.</a></li><li><a class="nounderline abstract_t">Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol 1990; 66:779.</a></li><li><a class="nounderline abstract_t">Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319:385.</a></li><li><a class="nounderline abstract_t">Kostis JB, Lacy CR, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997; 133:550.</a></li><li><a class="nounderline abstract_t">Hager WD, Davis BR, Riba A, et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. Am Heart J 1998; 135:406.</a></li><li><a class="nounderline abstract_t">Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996; 94:346.</a></li><li><a class="nounderline abstract_t">Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547.</a></li><li><a class="nounderline abstract_t">Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.</a></li><li><a class="nounderline abstract_t">de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J 2000; 139:185.</a></li><li><a class="nounderline abstract_t">Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335:1107.</a></li><li class="breakAll">Data presented at the 49th Annual Scientific Session of the ACC, Anaheim, CA, March, 2000.</li><li><a class="nounderline abstract_t">O'Connor CM, Carson PE, Miller AB, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998; 82:881.</a></li><li><a class="nounderline abstract_t">Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000; 139:503.</a></li><li><a class="nounderline abstract_t">Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. Br Heart J 1995; 73:428.</a></li></ol></div><div id="topicVersionRevision">Topic 3455 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741058" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242521" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984898" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3316343" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220572" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899840" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The effect of diltiazem on mortality and reinfarction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141377" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506325" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759075" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3520315" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264493" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650289" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813041" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813041" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781971" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10689266" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7786657" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
